// ADVOCACY
Innovative medicines as drivers of economic security – a strategic imperative for G7 economies
Against a backdrop of growing geopolitical uncertainty, governments are reassessing what competitiveness and economic security mean in practice. Success critically depends on the ability to identify, understand, and support strategic sectors. The innovative pharmaceutical industry is a proven growth engine for G7 economies, powered by advances in innovative medicines and vaccines. The G7 now has both an opportunity and a strategic imperative to build on this strength
Dr David Reddy, Director General, IFPMA
A LEGACY WORTH BUILDING ON G7 countries have long been the home of pharma- ceutical innovation. These countries have built world-leading R&D ecosystems, fortified complex supply chains, shaped robust regulatory standards, and responded to global challenges with speed. These commitments and investments have not only trans- formed health outcomes for populations in those countries but have also generated significant eco- nomic growth. Decades of scientific progress have positioned the pharmaceutical industry as the world’s most research-intensive sector, channelling nearly one- third of gross value back into R&D – a rate that surpasses electronics, aerospace, and advanced manufacturing. 1 But as the global landscape for inno- vation is changing, this heritage must be built upon and not taken for granted as a guarantee of future success.
36 // G7 FRANCE: THE ÉVIAN SUMMIT 2026
Made with FlippingBook - professional solution for displaying marketing and sales documents online